Tandutinib phase 1 experience: patient characteristics
Characteristic . | Value . |
|---|---|
| Total number of patients enrolled, N | 40 |
| Males/females, n | 28/12 |
| Median age, y (range) | 70.5 (22-90) |
| AML, n | 39 |
| AML with antecedent MDS, n | 15 |
| MDS, n | 1 |
| FLT3-ITD, n | 8 |
| Median no. of prior therapeutic regimens (range) | 5.5 (1-10) |
| Complete response with any prior treatment, n | 16 |
| Unfavorable cytogenetics,* n/N | 6/35 |
Characteristic . | Value . |
|---|---|
| Total number of patients enrolled, N | 40 |
| Males/females, n | 28/12 |
| Median age, y (range) | 70.5 (22-90) |
| AML, n | 39 |
| AML with antecedent MDS, n | 15 |
| MDS, n | 1 |
| FLT3-ITD, n | 8 |
| Median no. of prior therapeutic regimens (range) | 5.5 (1-10) |
| Complete response with any prior treatment, n | 16 |
| Unfavorable cytogenetics,* n/N | 6/35 |
Unfavorable cytogenetics are defined as any of the following: -5, -7, 5q-, 7q-, 11q-, 11q23 abnormalities, 3q21 abnormalities, 3q26 abnormalities, and complex karyotypes.